Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALinC 17: Continuous Intensification for VHR-ALL
NCT00003783Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Mar 1999
- Primary completion
- Nov 2002
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Replacement Enzymes
- Countries
- 5
01
Overview
A Phase 2 trial of methotrexate, mercaptopurine, cytarabine, idarubicin, etoposide in acute lymphoblastic leukemia (ALL), sponsored by Children's Oncology Group. Started Mar 1999; status: completed.
02
Drugs
methotrexatemercaptopurinecytarabineidarubicinetoposide
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00003783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003783.